Sobi completes acquisition of Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout

Contributed by: PR Newswire

Tags

Sobi-Acq-Arthrosi

More Like This

Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout

PR Newswire associated0

Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.

Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout

Sobi showcases new data across rare inflammatory conditions at ACR 2025

Sobi to share new clinical data and research at EULAR 2025

FDA Accepts Biologics License Application for Sobi's NASP for Patients with Uncontrolled Gout

Invitation: Sobi's NASP and Uncontrolled Gout call and webcast

Sobi Q3 2024 report: Strong growth and significant pipeline momentum